Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

Zoetis Inc. (ZTS) Current Ratio: 3.03

Is Zoetis Inc.’s current ratio high or low?

Zoetis Inc.'s current ratio of 3.03 is in line with its 5-year average of 2.90, around the middle of its 5-year range (1.75–3.86).

As of Sunday, June 14, 2026. 26.78% above its 12-month average of 2.39.

ZTS Current Ratio Chart

ZTS Current Ratio
3.03+73.14% 1Y
Zoom

ZTS Average Current Ratio Chart

ZTS Current vs Average Current Ratio Chart

ZTS Current Ratio Metrics

CURRENT RATIO

3.03

CURRENT RATIO AVG TTM

2.39

CURRENT RATIO AVG 3Y

2.63

CURRENT RATIO AVG 5Y

2.90

CURRENT RATIO AVG 10Y

2.97

CURRENT RATIO AVG 15Y

2.88

CURRENT RATIO AVG 20Y

2.88

CURRENT VS TTM AVG

+26.78%

CURRENT VS 3Y AVG

+15.32%

CURRENT VS 5Y AVG

+4.36%

CURRENT VS 10Y AVG

+1.99%

CURRENT VS 15Y AVG

+5.05%

CURRENT VS 20Y AVG

+5.05%

ZTS Competitors' Current Ratio

NAMEMARKET CAPCURRENT RATIOTTM3Y5Y
Zoetis Inc. (ZTS)$33.36B3.032.392.632.90
Centene Corporation (CNC)$32.19B1.681.401.241.19
Medline Inc. (MDLN)$30.96B4.293.843.943.94
IQVIA Holdings Inc. (IQV)$30.29B0.750.790.830.90
Agilent Technologies, Inc. (A)$36.67B1.962.022.172.21
Biogen Inc. (BIIB)$29.53B2.682.022.252.11
DexCom, Inc. (DXCM)$29.08B1.881.672.043.15
Veeva Systems Inc. (VEEV)$25.92B4.894.704.394.08
Waters Corporation (WAT)$23.17B1.731.922.082.07
United Therapeutics Corporation (UTHR)$23.17B6.605.926.536.74

Liquidity Analysis

Current Ratio

3.03

Quick Ratio

1.94

Zoetis Inc. Current Ratio Formula & Definition

Current Ratio = Current Assets / Current Liabilities

The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Zoetis Inc. Current Ratio FAQ

What is the current ratio for Zoetis Inc. (ZTS)?
The current ratio for ZTS stock is 3.03.
Is Zoetis Inc.'s current ratio high or low?
Zoetis Inc.'s current ratio of 3.03 is in line with its 5-year average of 2.90, around the middle of its 5-year range (1.75–3.86).
What is the TTM average current ratio for Zoetis Inc. (ZTS)?
The TTM average current ratio for ZTS stock is 2.39.
What is the 3Y average current ratio for Zoetis Inc. (ZTS)?
The 3Y average current ratio for ZTS stock is 2.63.
What is the 5Y average current ratio for Zoetis Inc. (ZTS)?
The 5Y average current ratio for ZTS stock is 2.90.
What is the 10Y average current ratio for Zoetis Inc. (ZTS)?
The 10Y average current ratio for ZTS stock is 2.97.
What is the 15Y average current ratio for Zoetis Inc. (ZTS)?
The 15Y average current ratio for ZTS stock is 2.88.
What is the 20Y average current ratio for Zoetis Inc. (ZTS)?
The 20Y average current ratio for ZTS stock is 2.88.

Zoetis Inc. Current Ratio History

DATECURRENT RATIO
2025-12-313.03
2024-12-311.75
2023-12-313.36
2022-12-312.37
2021-12-313.86
2020-12-313.05
2019-12-312.63
2018-12-313.60
2017-12-313.85
2016-12-313.03
2015-12-312.15
2014-12-313.19
2013-12-312.37
2012-12-312.55
2011-12-312.74
2010-12-312.62

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck